

Presentation and Chair's address to the 2025 Annual General Meeting

30 October 2025

4DMedical Limited (ASX: 4DX, "4DMedical" or the "Company") attaches the following materials to be presented at the Annual General Meeting of Shareholders to be held today at 12:00pm AEDT:

1. Script of the prepared address to be given by the Chair; and
2. Presentation slides to accompany the meeting.

—ENDS—

Authorised by the 4DMedical Board of Directors.

Contacts

Corporate

Investor Relations

investor.relations@4dmedical.com

Administration

Company Secretary

companysecretary@4dmedical.com

Media Enquiries

Julia Maguire

julia@thecapitalnetwork.com.au

About 4DMedical

4DMedical Limited (ASX:4DX) is a global medical technology company revolutionizing respiratory care with advanced imaging and artificial intelligence. Its patented **XV Technology®** transforms standard scans into rich, functional insights that allow physicians to detect, diagnose, and monitor lung disease earlier and with greater precision.

4DMedical's expanding software portfolio includes the FDA-cleared **XV Lung Ventilation Analysis Software (XV LVAS®)**, **CT LVAS™**, and the ground-breaking **CT:VQ™** solution designed to set new benchmarks in cardiothoracic imaging by combining ventilation and perfusion analysis.

Delivered seamlessly through a Software-as-a-Service (SaaS) model, 4DMedical's solutions integrate into existing hospital infrastructure, enhancing physician productivity and enabling more personalized patient care. With the addition of advanced AI capabilities from its 2023 acquisition of **Imbio**, 4DMedical continues to push the boundaries of medical imaging to redefine how respiratory disease is understood and treated worldwide.

Learn more at www.4dmedical.com

Melbourne

Level 7 Melbourne Connect
700 Swanston Street
Carlton VIC 3053
Tel: +61 (3) 9545 5940

Los Angeles

21255 Burbank Boulevard
Suite 120
Woodland Hills CA 91367
Tel: +1 (818) 403-8490

4DMedical Limited
ABN: 31 161 684 831
Email: info@4DMedical.com
www.4DMedical.com



4DMedical Limited

2025 Annual General Meeting

Chair's Address

12:00pm, Thursday, 30 October 2025

Firstly, my thanks to you, our shareholders. We are grateful for your support and participation throughout the year, including the recent exercise of \$22.6m of quoted options at almost 100% take-up. I also welcome new shareholders to 4DMedical.

The Board shares the excitement in the market for our products and the size of the commercial opportunity. In FY25 we advanced our strategic plan and are well positioned for scale with transformational products, deeper collaboration with industry and commercial partners including the Philips' agreement.

We have consolidated our offerings into a comprehensive product suite providing functional and structural lung scans; reaching more sites across wider geographies. FY25 saw a 95% increase in underlying SaaS revenue. We delivered almost 200,000 scans across 388 sites globally underscoring the growing utility of our portfolio.

The highlight of the year was CT:VQ™. In the space of two months we achieved FDA clearance, U.S. reimbursement and our first commercial contract; we will talk more on this during the AGM.

Total Income for FY25 was \$16.5 million, comprising operating revenue of \$5.9 million and other income of \$10.6 million. Net underlying expenditure for FY25 was \$35.6m (reported operating expenditure, offset by eligible Grant Income and one-off restructuring and Imbio integration costs). We reduced our cost base early in 2025 delivering savings and focusing on commercial objectives. The Board and leadership team balance a high level of ambition with careful stewardship of resources. We made purposeful investments in U.S. go-to-market initiatives, clinical validation, regulatory advancement, and major global industry conferences – investments that are already delivering strong outcomes.

At the end of the September 2025, the Company had a strong cash balance of \$33.5 million. In addition there are options with a potential of \$30million of capital to be exercised by 31st December 2025 which are comfortably in the money.

4DMedical has the right product portfolio to capitalise on a very large worldwide market. Our focus is to build on the growing momentum and take advantage of this opportunity. I want to share three highlights.

1. CT:VQ

CT:VQ™ is the world's first and only non-contrast, ventilation-perfusion (VQ) imaging solution. It will remove many barriers to care inherent in existing procedures: reducing cost, improving productivity, enhancing patient experience, and increasing access.

The global commercial opportunity for CT:VQ™ is immense.

For personal use only



U.S. reimbursement for CT:VQ™ is a pivotal milestone making the product more readily accessible across over 4,000 Medicare-certified hospitals in the U.S. This benchmark also provides a solid reference point for private payers.

The Board is delighted with the pace of FDA clearance and U.S. reimbursement and congratulates 4DMedical's product and regulatory teams.

We have also reported our first CT:VQ™ commercial contract with Stanford Medicine, a global leader in respiratory imaging. Stanford's commercial deployment is key to our rollout strategy building a network of Key Opinion Leaders at leading U.S. Academic Medical Centres.

2. Lung Health Screening

4DMedical is winning global contracts for Lung Health Screening. Our partnership with AstraZeneca in Brazil has gained great momentum in a short time frame. Within weeks of launch the Brazil program has added five additional hospitals. This demonstrates the scalability of our products within large-scale population health initiatives.

We are also supporting Lung Health Screening in Australia with Spectrum Medical Imaging.

3. Product rollout in Australia

4DMedical continues to expand Australian access to CT LVAS™, delivering scans through I-MED Radiology Network, Integral Diagnostics, Qscan, Spectrum Medical Imaging, Perth Radiology and Jones Radiology. This spread also provides us with a great basis for adoption of CT:VQ™ in Australia.

I am grateful to my fellow Directors and thank them for their commitment and stewardship. My sincere thanks to our extraordinary global team who have achieved much in FY25 and are executing our FY26 plan with energy, dedication and diligence.


With the momentum built over the past 12 months, especially the inflection created by CT:VQ™, I look to the year ahead with great confidence.

On behalf of the Board of 4DMedical, thank you for your attendance today and I kindly seek your approval of the resolutions placed before you.



4D Medical Limited (ASX:4DX)
Annual General Meeting
30 October 2025

Leading Cardiopulmonary Imaging into the Next Era



Copyright © 4D Medical Limited 2025
Level 7, Melbourne Connect
700 Swanston Street
Melbourne, Victoria 3053
Australia
ABN 31 161 684 831
www.4dmedical.com

For personal use only

Disclaimer



This presentation has been prepared by 4DMedical Limited (ACN 161 684 831) (**Company** or **4DMedical**). This presentation contains summary information about the Company, its subsidiaries and the entities, businesses and assets they own and operate (**Group**) and their activities current as of 30 October 2025 unless otherwise stated and the information remains subject to change without notice. This presentation contains general background information and does not purport to be complete. No attempt has been made to independently verify the information contained in this presentation.

Not an offer or financial product advice

The Company is not licensed to provide financial product advice. This presentation is not and should not be considered, and does not contain or purport to contain, an offer or an invitation to sell, or a solicitation of an offer to buy, directly or indirectly, any securities to any person in any jurisdiction to whom or in which such offer or solicitation is unlawful nor shall it (or any part of it), or the fact of its distribution, form the basis of, or be relied on in connection with or act as any inducement or recommendation to enter into, any contract whatsoever relating to any securities.

This presentation is for information purposes only and is not a prospectus, product disclosure statement, pathfinder document for the purposes of section 734(9) of the Australian *Corporations Act 2001* (Cth) (**Corporations Act**) or other offer document under Australian law or the law of any other jurisdiction. This presentation does not constitute an invitation to apply for or purchase securities and does not include any application form for securities. This presentation does not constitute an advertisement for an offer or proposed offer of securities. Neither this presentation nor anything contained in it shall form the basis of any contract or commitment and it is not intended to induce or solicit any person to engage in, or refrain from engaging in, any transaction. Nothing in this presentation constitutes legal, financial, tax or other advice. Recipients of the presentation should conduct their own investigation, evaluation and analysis of the business and other data and information set out in the presentation.

The distribution of this presentation in jurisdictions outside Australia may be restricted by law and you should observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of applicable securities laws. In particular, this presentation may not be distributed or released in the United States. The securities in the Company (**Securities**) have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (**U.S. Securities Act**), or the securities laws of any state or other jurisdiction of the United States. Accordingly, the Securities may not be offered or sold, directly or indirectly, in the United States, unless they have been registered under the U.S. Securities Act (which the Company has no obligation to do or procure) or are offered or sold in a transaction exempt from, or not subject to, the registration requirements of the U.S. Securities Act and applicable securities laws of any state or other jurisdiction of the United States.

Agenda

- For personal use only
1. Opening & introductions
 2. Chair's address
 3. CEO's address
 4. Procedural matters
 5. Formal business
 6. Closing remarks

Board of Directors – significant medical and commercial sector experience



For personal use only



LIL BIANCHI

Non-Executive Chair
Chair, Audit & Risk Committee

Experienced contributor of business transformations for US listed technology companies with a beneficial technology product expertise in AI and SaaS offerings.



Dr ANDREAS FOURAS PhD

Managing Director and CEO

Award-winning aerospace engineer and innovator responsible for the conception and development of 4DMedical's core technologies.



JULIAN SUTTON

Non-Executive Director
Chair, Remuneration & Nomination Committee

Chartered Financial Analyst who began his career as an actuarial analyst in Melbourne before moving into funds management with Schroders and Credit Suisse in London.



Dr GERALDINE MCGINTY MD

Non-Executive Director

Internationally recognised expert in health care strategy and imaging economics, and prominent advocate for patient-centred care. Professor of Radiology and Population Health Sciences at Weill Cornell Medicine in New York City.



Dr ROBERT A. FIGLIN MD

Non-Executive Director
Chair, Medical Advisory Committee

Globally recognised leader in genitourinary and thoracic oncology, as well as Editor of the Kidney Cancer Journal and Spielberg Family Chair in Hematology/Oncology at Cedars Sinai.



JOHN LIVINGSTON

Non-Executive Director


Founding partner of ASX listed Integral Diagnostics (ASX:IDT) and an industry leader in the implementation of PACS and RIS in radiological settings.

Chair's address



Lil Bianchi

Non-Executive Chair



CEO's address



Dr Andreas Fouras PhD

Managing Director & CEO




The leading pulmonary & cardiothoracic imaging software company in the market

4DMedical was founded in Melbourne in 2013 to bring breakthrough lung function imaging technologies to patient care. Listed on the ASX in 2020. In Dec. 2023, we acquired USA-based Imbio, Inc. to combine our unique structural and functional image analysis expertise.

Revenues and GTM teams heavily US focused

- Structural & Functional Imaging software
- 100+ patented technologies
- 9 FDA cleared devices
- 130 global team members
 - **US** Go-To-Market | **AU** Engineering, R&D and support
- Technical & clinical expertise
- Global brands supporting distribution


Pulmonary Function



XV LVAS®

Dynamic Ventilation Analysis (Fluoro)


FDA



CT LVAS™

CT-based Ventilation Analysis

FDA



CT:VQ™

Next Gen VQ (Ventilation + Perfusion)

FDA




Functional LDA

Air Trapping + Emphysema

FDA/CE


Pulmonary Structure



Lung Density

Emphysema, HAA, Fissures


FDA/CE



Lung Texture

ILD's / Fibrosis


CE



IQ-UIP™

IPF Screening

FDA




Lung Nodules

Lung Cancer (Partner Solution)

FDA/CE


Cardiovascular



CAC

Coronary Calcification

FDA/CE



PHA

Hypertension (RV/LV, MPA, Pa/Ao)


FDA/CE

CT:VQ™ All the CONTRAST. None of the INJECTIONS.


Value-adding the standard-of-care Chest CTs with Non-contrast functional imaging



Routine CT



CT:VQ™ Non-contrast Ventilation & Perfusion



Clinical Value

CT:VQ™ FDA Clearance



For personal use only

- ✓ **Transformational Milestone** - CT:VQ™ becomes the world's **first and only non-contrast**, CT-based ventilation-perfusion imaging technology to **receive FDA 510(k) clearance**.
- ✓ **Large Addressable Market** - Over **1M VQ scans annually in the U.S.**; USD **\$1.1B+ U.S. market**, USD **\$2.6B+ global** opportunity. Introduction of CT:VQ™ into the market will drive long-term growth in demand for ventilation-perfusion scans beyond the traditional nuclear VQ indications.
- ✓ **Instant Scalability** - Compatible with **14,500 CT scanners in the U.S.**, enabling broad adoption without new infrastructure.
- ✓ CT:VQ™ poised to displace nuclear VQ scans and expand functional lung imaging
 - ✓ **Clinical Validation** studies submitted as part of FDA 510(k)
 - ✓ **Commercial Traction** underway with pre-clearance sites already converting to commercial contracts

Key commercial, product & clinical milestones: FY25 to date



FDA clearance for CT:VQ™

- (U.S. Food and Drug Administration), the world's first lung ventilation and perfusion software imaging tool, coupled with U.S. **Reimbursement for CT:VQ™** from the U.S. Centers for Medicare and Medicaid Services (CMS) at US\$650.
- **Stanford University becomes the first U.S. Academic Medical Centre (AMC) to adopt CT:VQ™** under a commercial contract, **6-weeks post-clearance**.
- **U.S. Department of Defense (DoD) contract to supply CT:VQ™ scans** to assess lung health in a cohort of active-duty personnel.

Contract wins and renewals

- **Across multiple market segments and key reference sites globally**, displaying increased commercial momentum and uptake of 4DMedical's SaaS products.
- 4DMedical partners with **AstraZeneca** and **Spectrum Medical Imaging** to perform Lung Health Screening in Brazil and Australia, respectively.

Strategic partners

- **Strategic investment from industry partner Pro Medicus Limited**, strengthening balance sheet and unlocking distribution opportunities.
- 4DMedical signs reseller agreement to have **Philips as an authorised reseller throughout the U.S.**, representing a transformative commercial pathway for 4DMedical's product suite, leveraging Philips' long established and significant commercial partnerships.

Key evidence & clinical publications

- Multicentre trial involving **U.S. Veterans, published in Respiratory Research**, revealed unique functional biomarker signatures of early and subtle forms of small airways disease that are often missed by standard tests like spirometry and CT scans

Commercialisation Strategy



For personal use only


	US Government	US Commercial	Global Partnerships	Australia
Enablers			Olympus	I-MED
	Exclusive	Non-exclusive	AstraZeneca	Integral Diagnostics
	Reimbursement		Nuance/Aidoc	Jones, PRC, Spectrum
Sector	Veterans Affairs	Community-based Clinics	Global Pharma Companies	Community Clinics
	Department of Defense	Academic Institutes	Global Device Companies	Radiology Networks
	Federal & State Facilities	Health Systems (IDN's)	AI Marketplace Companies	Public Hospitals
		Radiology Networks		National Programs
Rationale	Unmet need to solve for respiratory issues, including deployment-related respiratory diseases (DRRD)	Largest lung diagnostic market with huge economic scale	Large burden of data needed where our technologies can accelerate progress	Early adoption of core technologies in key players to build influence and scale
	PACT Act - US\$280 billion commitment over ten years, covers numerous respiratory illnesses as presumptive conditions. Healthcare eligibility to 3.5 million post-9/11 veterans. Bi-partisan support of veteran care. Philips has long established and significant existing partnerships	Reimbursement rates established covering 4,000 facilities. Over 14.5k CT scanners deployed. Shortage of clinicians creates opportunity for AI tools and faster clinical insights	Custom imaging biomarker development and patient selection tools shorten clinical trial time and expense in the multi billion-dollar pharma development sector. AI marketplaces increase access and coverage through deployment capabilities	Australian radiology is innovative and readily accessible through community practices, networks and hospitals, with a high proportion of CT Scanners (33.9%) . Chest CT procedures through Medicare = 330k per annum. Proximity and collaboration with our development team speeds innovation.

4DMedical SaaS revenue building momentum, driven by increased fundamentals of layering growth in site numbers and scan volume, throughout FY2025




For personal use only

Global sites delivering 4DMedical scans




4DMedical delivering XV Technology® at 388 sites globally at 30 June 2025, growing 60% year-on-year, reflecting sustained growth across our Radiology and Hospital networks, third party distributor networks, and Olympus SeleCT™ screening sites.

Structural & Functional Scan Analysis



4DMedical delivered 194,789 scans in FY25, with over 74,000 scans in Q4 FY25 alone, up 35% quarter-on-quarter. Significant uplift driven by the subscription-based product portfolio, notably LDAi™, LDAf™, SeleCT™ screening, IQ-UIP™ analysis, as well as research and demonstration sites.

Group Operating Revenue




Underlying SaaS revenue up 95% year-on-year when adjusting for contractual true-up payments, and scanner lease and maintenance income. Group operating revenue of \$5.9 million, with gross margins >90%, up 56% on a reported basis.

Built the fundamentals, significant multipliers in play during 2025 and beyond



For personal use only



Procedural matters

For personal use only

Formal Business

For personal use only

Items of Business



- For personal use only
- Item 1:** Financial Report, Directors' Report and Auditors Report
 - Item 2:** Remuneration Report
 - Item 3:** Spill Resolution
 - Item 4:** Re-election of Directors – Mr John Livingston and Mr Julian Sutton
 - Item 5:** Proposed issue of Equity Securities to Directors – Ms Lil Bianchi, Mr John Livingston, Mr Julian Sutton, Dr Robert A Figlin and Dr Geraldine McGinty
 - Item 6:** Proposed issue of Equity Securities to Directors in lieu of director fees – Ms Lil Bianchi, Mr John Livingston, Mr Julian Sutton, Dr Robert A Figlin and Dr Geraldine McGinty
 - Item 7:** Grant of Options to the Managing Director and CEO
 - Item 8:** Resolution withdrawn
 - Item 9:** Approval in respect of the Tax-Exempt Employee Share Plan
 - Item 10:** Renewal of Proportional Takeover Provisions in Constitution

Item 1: Financial Report, Directors' Report and Auditors Report

To receive and consider the Financial Report of the Company and its controlled entities and the Reports of the Directors and Auditor for the year ended 30 June 2025.

For personal use only

For personal use only

Item 2: Remuneration report

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That the Remuneration Report, as contained in the Directors’ Report for the year ended 30 June 2025, is adopted.”

In Favour	Against	Proxy Discretion	Abstain
23,611,761	3,623,623	7,127,726	1,220,093
68.71%	10.55%	20.74%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 2.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 3: Spill Resolution

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

- That, for the purposes of section 250V(1) of the Corporations Act and for all other purposes, approval is given for:
- (a) the Company to hold another meeting of Shareholders within 90 days of the date of this meeting (**Spill Meeting**);
 - (b) all Vacating Directors cease to hold office immediately before the end of the Spill Meeting; and
 - (c) resolutions to appoint persons to offices that will be vacated pursuant to (b) to be put to vote at the Spill Meeting.

In Favour	Against	Proxy Discretion	Abstain
6,139,489	19,108,254	8,496,065	1,839,395
18.19%	56.63%	25.18%	

Further Information:

- The Board unanimously recommends that Shareholders vote against Item 3.
- The Chair of the meeting intends to vote undirected proxies against item 3.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Items 4A and 4B: Re-election of Directors

Item 4A

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of clause 13.3(b) of the Constitution, Listing Rule 14.4, and for all other purposes, **Mr John Livingston**, a non-executive Director appointed on 7 March 2018 and last re-elected on 3 November 2022, retires in accordance with clause 13.3(a) of the Constitution, and being eligible, is re-elected as a Director.”

In Favour	Against	Proxy Discretion	Abstain
22,804,777	2,781,993	7,241,241	2,755,192
69.47%	8.47%	22.06%	

Item 4B

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of clause 13.3(b) of the Constitution, Listing Rule 14.4, and for all other purposes, **Mr Julian Sutton**, a non-executive Director appointed on 15 September 2017 and last re-elected on 3 November 2022, retires in accordance with clause 13.3(a) of the Constitution, and being eligible, is re-elected as a Director.”

In Favour	Against	Proxy Discretion	Abstain
19,529,617	7,995,672	7,225,874	832,040
56.20%	23.01%	20.79%	

Items 5A to 5E: Proposed issue of Equity Securities to Directors

Item 5A

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:
 “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 196,149 Options to **Ms Lil Bianchi** (or her nominee) under the Incentive Plan on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
22,539,767	4,766,353	7,128,202	1,141,458
65.46%	13.84%	20.70%	

Item 5B

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:
 “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 129,280 Options to **Mr John Livingston** (or his nominee) under the Incentive Plan on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
19,971,455	5,403,313	7,133,592	3,067,420
61.43%	16.62%	21.94%	

Item 5C

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:
 “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 129,280 Options to **Mr Julian Sutton** (or his nominee) under the Incentive Plan on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
21,118,550	5,347,642	7,968,130	1,141,458
61.33%	15.53%	23.14%	

Items 5A to 5E: Proposed issue of Equity Securities to Directors (continued)

Item 5D

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:
 “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 129,280 Restricted Stock Units to **Dr Robert A. Figlin** (or his nominee) under the Incentive Plan on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
22,362,180	4,755,320	7,127,592	1,330,688
65.30%	13.89%	20.81%	

Item 5E

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:
 “That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 129,280 Restricted Stock Units to **Dr Geraldine McGinty** (or her nominee) under the Incentive Plan on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
22,352,824	4,755,320	7,136,948	1,330,688
65.27%	13.89%	20.84%	

Further Information:

- As the Board (excluding the CEO) have an interest in the matter, the Board has declined to make a recommendation with respect to voting on item 5A – 5E (inclusive)
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Items 6A to 6E: Approval for the proposed issue of securities to Directors in lieu of base directors' fees

Item 6A

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:
 "That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 112,245 Options to **Ms Lil Bianchi** (or her nominee) in lieu of director fees under the Incentive Plan on the terms and conditions set out in the Explanatory Statement."

Item 6B

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:
 "That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 118,368 Options to **Mr John Livingston** (or his nominee) in lieu of director fees under the Incentive Plan on the terms and conditions set out in the Explanatory Statement."

Item 6C

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:
 "That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 193,878 Options to **Mr Julian Sutton** (or his nominee) in lieu of director fees under the Incentive Plan on the terms and conditions set out in the Explanatory Statement."

In Favour	Against	Proxy Discretion	Abstain
24,443,360	2,573,347	7,328,775	1,230,298
71.17%	7.49%	21.34%	

In Favour	Against	Proxy Discretion	Abstain
22,548,55	2,534,054	7,338,131	3,155,040
69.55%	7.82%	22.63%	

In Favour	Against	Proxy Discretion	Abstain
24,538,934	2,478,383	7,328,775	1,229,688
71.45%	7.22%	21.34%	

Items 6A to 6E: Approval for the proposed issue of securities to Directors in lieu of base directors' fees (continued)

Item 6D
To consider, and if thought fit, to pass, the following as an **ordinary** resolution:
"That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 173,470 Restricted Stock Units to **Dr Robert A. Figlin** (or his nominee) in lieu of director fees under the Incentive Plan on the terms and conditions set out in the Explanatory Statement."

Item 6E
To consider, and if thought fit, to pass, the following as an **ordinary** resolution:
"That, for the purposes of Listing Rule 10.14 and for all other purposes, Shareholders approve the proposed issue of 84,184 Restricted Stock Units to **Dr Geraldine McGinty** (or her nominee) in lieu of director fees under the Incentive Plan on the terms and conditions set out in the Explanatory Statement."

Further Information:

- As the Board (excluding the CEO) have an interest in the matter, the Board has declined to make a recommendation with respect to voting on item 6A – 6E (inclusive)
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

In Favour	Against	Proxy Discretion	Abstain
24,519,214	2,489,493	7,474,442	1,092,631
71.10%	7.22%	21.68%	

In Favour	Against	Proxy Discretion	Abstain
24,519,374	2,489,943	7,336,775	1,229,688
71.39%	7.25%	21.36%	

Item 7: Grant of Options to the Managing Director and CEO

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of Listing Rule 10.14, sections 200B and 200E of the Corporations Act and for all other purposes, Shareholders approve the proposed grant of up to 4,568,275 Options, and potential termination benefits, to Managing Director and CEO, Dr Andreas Fouras, under the Incentive Plan and on the terms described in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
19,704,291	8,265,126	7,329,945	283,841
55.82%	23.41%	20.77%	

Further Information:

- The Board (other than Dr Fouras) unanimously recommends that Shareholders vote in favour of Item 7.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

Item 8: Resolution withdrawn

For personal use only

Item 9: Approval in respect of the Tax-Exempt Employee Share Plan

To consider, and if thought fit, to pass, the following as an **ordinary** resolution:

“That, for the purposes of Listing Rules 7.1 and 7.2 Exception 13 and for all other purposes, the rules of the 4D Medical Tax-Exempt Employee Share Plan (which are summarised in the Explanatory Statement accompanying this Notice) and the future issues of shares under that plan, be approved, on the terms and conditions set out in the Explanatory Statement.”

In Favour	Against	Proxy Discretion	Abstain
25,487,097	1,177,266	7,357,835	1,736,629
74.91%	3.46%	21.63%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 9.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

For personal use only

Item 10: Renewal of Proportional Takeover Provisions in Constitution

To consider, and if thought fit, to pass, the following as a **special** resolution:

“That, for the purposes of section 648G(4) of the Corporations Act and for all other purposes, the Shareholders approve the renewal of the proportional takeover provisions in clause 11 of the Constitution of the Company for a period of three (3) years from the date of the Meeting.”

In Favour	Against	Proxy Discretion	Abstain
26,818,837	262,389	7,331,115	1,623,009
77.93%	0.76%	21.30%	

Further Information:

- The Board unanimously recommends that Shareholders vote in favour of Item 10.
- The Chair of the meeting intends to vote undirected proxies in favour of the Item.
- The voting exclusion for this item is as disclosed in the Notice of Meeting.

For personal use only

Poll

For personal use only



4D Medical Limited (ASX:4DX)
Annual General Meeting
30 October 2025

Copyright © 4D Medical Limited 2025
Level 7, Melbourne Connect
700 Swanston Street
Melbourne, Victoria 3053
Australia

www.4dmedical.com

ABN 31 161 684 831